Local News

• AstraZeneca and POZEN announce PN 400 Phase III study results  AstraZeneca and POZEN, co-development partner for the investigational compound PN 400, announced results from two Phase III studies, PN 400-301 and PN 400-302 comparing PN 400 to enteric-coated naproxen 500 mg. These studies were conducted by POZEN under an agreed Special FDA Protocol Assessment.
  AstraZeneca December 03, 2008  
• Isis Announces survival advantage in prostate cancer study  Isis announced that OncoGenex Pharmaceuticals provided positive survival results from a randomized Phase 2 clinical trial of OGX-011 in combination with docetaxel and prednisone compared to docetaxel and prednisone alone for first-line treatment of metastatic castrate resistant prostate cancer.
  Isis Pharmaceuticals, Inc. December 03, 2008  
• Wyeth submits European marketing authorization application for its 13-Valent Vaccine  Wyeth Pharmaceuticals announced that it has submitted a marketing authorization application to the European Medicines Agency for approval to market its investigational 13-valent pneumococcal conjugate vaccine (PCV13) for infants and young children.
  Wyeth Pharmaceuticals December 03, 2008  
• Medtronic receives FDA approval of Sprint Quattro Secure S Single Coil Defibrillation Lead  Medtronic announced U.S. FDA approval of the Medtronic Sprint Quattro Secure® S single coil defibrillation lead (Model 6935) for use with implantable defibrillators in patients at risk for dangerous tachyarrhythmias (fast heartbeats) and sudden cardiac arrest.
  Medtronic, Inc. December 03, 2008  
• Forest Laboratories responds to unsolicited mini-tender offer  Forest Laboratories has been notified of an unsolicited mini-tender offer by TRC Capital Corporation of Toronto, Canada, a private investment company. Forest Laboratories has received a copy of the tender offer to purchase up to 3.0 million outstanding shares of the company's common stock.
  Forest Laboratories, Inc. December 03, 2008  
• Cell Genesys and Takeda terminate collaboration agreement for GVAX Immunotherapy  Cell Genesys and Takeda Pharmaceutical have mutually agreed to suspend the further development of GVAX immunotherapy for prostate cancer and that Takeda has ended the collaboration agreement with Cell Genesys for the development and commercialization of the product.
  Cell Genesys, Inc. December 03, 2008  
• Transgenomic licenses Power3 Medical Products’ neurodegenerative diagnostics  Transgenomic and Power3 Medical Products announced a letter of intent to acquire exclusive rights for Power3 Medical’s Neurodegenerative Biomarkers, which include NuroPro®, a proposed diagnostic for Alzheimer’s and Parkinson’s disease.
  Transgenomic, Inc. December 03, 2008  
• Introgen files Chapter 11 petition to facilitate restructuring  Introgen has filed Chapter 11 petitions, and expects that the process will facilitate the company's recently announced strategic reorganization, including a sales procedures motion that will allow Introgen to market its therapeutic portfolio and other assets to prospective buyers.
  Introgen Therapeutics, Inc. December 03, 2008  
• Monsanto Company completes acquisitions of CanaVialis and Alellyx  Monsanto announced that it has completed its proposed acquisition of Aly Participacoes, which operates the sugarcane breeding and technology companies, CanaVialis and Alellyx, both of which are based in Brazil.
  Monsanto Company December 02, 2008  
• Monsanto to leverage its technology to enhance yield and economic value for farmers  As farmers in the U.S. are making their initial seed purchase decisions for the 2009 growing season, Monsanto Company plans to discuss the reasons behind its confidence that it can make good on its commitment to more than double its fiscal 2007 gross profit by 2012.
  Monsanto Company December 02, 2008  

   (next 10 articles)